Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

Kimberly Retzlaff  |  Issue: September 2016  |  September 8, 2016

paulista/shutterstock.com

paulista/shutterstock.com

The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung C. Kim, MD, ScD, MSCE, Brigham and Women’s Hospital, Boston.

Dr. Kim is the lead author of “Utilization of the first biosimilar infliximab since its approval in South Korea,” which appeared in Arthritis & Rheumatology in May 2016. The study demonstrated that the introduction of biosimilar infliximab in South Korea led to a significant increase in prescriptions for the new drug, as well as decreases in the price of the brand-name reference drug.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Aside from pricing considerations, inherent concerns exist with introducing a new class of drug to market, not the least of which is clinical efficacy and safety. The FDA’s potential fast-track approval process means that practicing rheumatologists will soon have another drug in their arsenal against rheumatic disease, and likely many more to follow.

Background

The FDA defines a biosimilar as “a biological product that is approved based on a showing that it is highly similar to an FDA-approved biological product, known as a reference product, and has no clinically meaningful differences in terms of safety and effectiveness from the reference product.”2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Congress passed the Biologics Price Competition and Innovation Act, part of the Affordable Care Act, in 2009 in an attempt to slow upward trends in the price of biologic medications and to encourage the availability of less expensive treatments. The legislation effectively created the potential for a faster approval pathway for products that are biosimilar to or interchangeable with an FDA-licensed reference product. The FDA also published The Purple Book, an online reference that lists biologics with reference-product exclusivity, as well as the biosimilars and interchangeables (i.e., a product that is biosimilar to an FDA-approved reference product and meets additional standards for interchangeability) for each.

The FDA requires manufacturers of biosimilars to prove the drug is as safe and effective as the reference drug for approval. To date, there are few long-term studies to support the clinical safety and efficacy of biosimilar drugs for rheumatic disease, according to Dr. Kim, but more research is being published on the subject. One study showed the safety and efficacy of CT-P13, a biosimilar to Remicade, among European patients with inflammatory bowel disease.3 Multinational studies of CT-P13 showed comparable efficacy and safety over 54 weeks among patients with active rheumatoid arthritis and an inadequate response to methotrexate and ankylosing spondylitis.4,5

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biosimilarsdrug updateinfliximabprescriptionpricingrheumatologistrheumatology

Related Articles

    Marching to the Biosimilar Beat: Questions on Rollout Remain

    September 7, 2023

    The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    April 15, 2016

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

    The Biosimilars Debate Heats Up: Potential cost savings weighed against patient health & safety

    March 1, 2016

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

    Report on EU’s Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar?

    October 17, 2017

    As questions about biosimilar medications swirl among U.S. rheumatologists, a recently released report sheds some light on the European experience with biosimilars—and may offer some important insights for the U.S. market. The report, Biosimilars in the EU: Information Guide for Healthcare Professionals, was released in late April by the European Medicines Agency (EMA) and the…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences